Recursion Pharmaceuticals Management
Management criteria checks 3/4
Recursion Pharmaceuticals' CEO is Chris Gibson, appointed in Nov 2013, has a tenure of 10.42 years. total yearly compensation is $6.32M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.083% of the company’s shares, worth $1.49M. The average tenure of the management team and the board of directors is 3.2 years and 8.7 years respectively.
Key information
Chris Gibson
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 7.9% |
| CEO tenure | 10.4yrs |
| CEO ownership | 0.08% |
| Management average tenure | 3.2yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat
May 16Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$328m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$260m |
| Mar 31 2023 | n/a | n/a | -US$249m |
| Dec 31 2022 | US$6m | US$498k | -US$239m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$212m |
| Dec 31 2021 | US$674k | US$485k | -US$186m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$124m |
| Mar 31 2021 | n/a | n/a | -US$99m |
| Dec 31 2020 | US$3m | US$270k | -US$87m |
Compensation vs Market: Chris's total compensation ($USD6.32M) is about average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Gibson (40 yo)
10.4yrs
Tenure
US$6,315,903
Compensation
Dr. Christopher C. Gibson, also known as, Chris, Ph.D. is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive Officer and Director since November 2013. Previously, Dr. Gibson wa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.4yrs | US$6.32m | 0.083% $ 1.5m | |
| COO & President | 5.8yrs | US$2.76m | 0.091% $ 1.6m | |
| Co-Founder & Director | 11.3yrs | US$283.14k | 3.07% $ 54.9m | |
| Chief Financial Officer | 4.1yrs | US$2.09m | 0.37% $ 6.7m | |
| Vice President of Finance & Accounting | no data | no data | no data | |
| Chief Technology Officer | 4.3yrs | no data | no data | |
| Senior Director of Investor Relations | 1.9yrs | no data | no data | |
| Chief Legal Officer & General Counsel | less than a year | no data | no data | |
| Chief Communications Officer | 1.9yrs | no data | no data | |
| Chief Corporate Development Officer and SVP of Business Development & Corporate Initiatives | less than a year | no data | no data | |
| Vice President of People Operations | no data | no data | no data | |
| Chief Business Operations Officer | 2.3yrs | no data | no data |
3.2yrs
Average Tenure
40yo
Average Age
Experienced Management: RXRX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.4yrs | US$6.32m | 0.083% $ 1.5m | |
| Co-Founder & Director | 11.3yrs | US$283.14k | 3.07% $ 54.9m | |
| Chief R&D Officer | no data | no data | no data | |
| Independent Chair of the Board | 4yrs | US$318.14k | 0.020% $ 360.8k | |
| Member of Business Advisory Panel | 9.8yrs | no data | no data | |
| Chairman of Therapeutics Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 4.1yrs | US$293.14k | 0.011% $ 197.6k | |
| Co-Founder & Independent Director | 10.4yrs | US$290.64k | 1.34% $ 24.0m | |
| Member of Scientific and Technical Advisory Board | 10yrs | no data | no data | |
| Member of Scientific & Technical Advisory Board | 10yrs | no data | no data | |
| Independent Director | 7.6yrs | US$298.14k | 0.033% $ 580.9k | |
| Independent Director | 4yrs | US$298.14k | 0.019% $ 332.2k |
8.7yrs
Average Tenure
59yo
Average Age
Experienced Board: RXRX's board of directors are considered experienced (8.7 years average tenure).